Practica Capital participates in Atrandi's $25M Series A funding round
Atrandi Biosciences, a life sciences company pioneering next-generation single-cell analysis technology, today announced a $25 million Series A funding round led by Lux Capital, with participation from Practica Capital, Vsquared Ventures, Metaplanet, and GRIDS Capital. This investment will accelerate the company's expansion into the U.S. market, support the growth of its semi-permeable capsule (SPC) technology, and advance new product development to enable breakthrough scientific discoveries.
“Atrandi was founded to bridge a fundamental gap in biological research - the need for high-throughput, scalable technologies to manipulate and analyze single cells with precision,” said Juozas Nainys, Ph.D., CEO & Co-Founder, Atrandi Biosciences. “Our SPC technology is a fundamental breakthrough born from a need to overcome the limitations of existing single-cell analysis tools, allowing researchers to generate rich datasets with unprecedented combination of throughput, multimodality, and data quality. This funding enables us to broaden our product portfolio, strengthen our U.S. presence, and better serve our customers. We’re here to deliver on our vision and help realize the full potential of the Century of Biology.”
“Biological research is entering a new era, and Atrandi is uniquely positioned to equip scientists with the tools to tackle the most complex biological challenges,” said David Yang, Partner, Lux Capital. “By advancing SPC-based workflows, Atrandi empowers researchers to unlock new biological insights that will reshape our understanding of life and disease.”
“We are living in the century of biology, where advances in life sciences are rewriting the rules of medicine,” added Lise Rechsteiner, General Partner, Vsquared Ventures. “Atrandi Biosciences is bridging the gaps between genetic data, molecular activity, and cellular behavior, enabling breakthroughs that will drive the future of human health.”
Newer
There are no newer news